Tawara K, Kawashima K, Ishikawa H, Yamamoto K, Saito K, Ebihara A, Yoshida S
Eur J Clin Pharmacol. 1981 Feb;19(3):197-203. doi: 10.1007/BF00561949.
The disposition of propranolol stereoisomers after administration of a single oral dose of the racemic drug was investigated in seven hyperthyroid patients before and after antithyroid drug therapy. The possibility of hypersensitivity to propranolol in the patients was evaluated by constructing plasma propranolol concentration -- beta-blocking effect curves. There was no statistically significant difference in elimination half-life (t1/2) between (+/-)- and (-)-propranolol before and after antithyroid drug therapy. However, the plasma clearance (Vp) of (-)-propranolol was smaller than that of (+/-)-propranolol, and the difference was statistically significant after antithyroid drug therapy. Vp decreased or did not change in young patients after therapy. No significant difference was observed in the relationship between the tilt-induced pulse rate response and plasma propranolol concentration when treated patients became euthyroid compared to their response in the hyperthyroid state.
在七名甲状腺功能亢进患者接受抗甲状腺药物治疗前后,研究了单次口服消旋普萘洛尔后其立体异构体的处置情况。通过构建血浆普萘洛尔浓度 - β受体阻滞效应曲线,评估了患者对普萘洛尔过敏的可能性。抗甲状腺药物治疗前后,(±)-普萘洛尔和(-)-普萘洛尔的消除半衰期(t1/2)无统计学显著差异。然而,(-)-普萘洛尔的血浆清除率(Vp)低于(±)-普萘洛尔,抗甲状腺药物治疗后差异具有统计学意义。治疗后年轻患者的Vp降低或未改变。与甲状腺功能亢进状态下的反应相比,治疗后甲状腺功能正常的患者在倾斜诱发的心率反应与血浆普萘洛尔浓度之间的关系上未观察到显著差异。